Related Experiment Video
Updated: May 23, 2026
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
High-throughput screening for novel drug combinations using patient-derived organoids
Natalie Thielen1, Chaoyuan Kuang2, Edward Chu2
1Montefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.
Abstract:
Patient-Derived Organoids (PDO) are 3D culture systems that mimic human tissues more accurately than traditional 2D cell lines. They maintain cellular diversity, spatial layout, and patient-specific traits, making them essential for high-throughput screening (HTS). Due to tumor heterogeneity and cancer therapies resistance, combination screening has become increasingly important. Moreover, recent advancements now enable larger-scale combination studies. Standardized matrices improve uniformity and reproducibility, while smaller plate formats and automation streamline seeding, dosing, and overall workflow. Microfluidic systems add further flexibility by enabling precise concentration gradients and sequential treatment delivery, expanding the range of possible combination designs. Meanwhile, assay readouts now extend well beyond viability as a single endpoint. Label free imaging, quantitative morphology, growth dynamics, and lineage related features now provide more sensitive and informative measures of both cytostatic and cytotoxic responses across organoid models. Diverse analytics are essential for understanding combination responses. Dose-response metrics and growth rate-adjusted parameters consider differences in baseline growth, while established combination calculations provide visualized ways to measure synergy across complex dose matrices. This comprehensive review synthesizes current knowledge on PDO-based HTS, with emphasis on technological strategies for adapting PDOs to screening platforms; design considerations for combination screening; analytical methodologies and readout technologies; challenge and limitation of PDO-based HTS and future development. Taken together, PDO-based HTS can be a powerful approach for identifying and refining therapeutic combinations. Ongoing progress in assay standardization, automation, micro-engineered delivery, and integrated analysis will improve the discovery of effective and applicable combination treatments, accelerate translation into precision medicine.
Insights
Patient-Derived Organoids (PDO) offer advanced 3D tissue models for high-throughput screening (HTS). Technological advancements in PDO-based HTS enhance combination therapy discovery for precision medicine.
Area of Science:
- Biotechnology
- Cancer Research
- Drug Discovery
Background:
- Patient-Derived Organoids (PDO) represent 3D culture systems that more accurately mimic human tissues than 2D cell lines.
- PDOs preserve patient-specific traits, cellular diversity, and spatial layout, making them crucial for high-throughput screening (HTS).
- Tumor heterogeneity and therapy resistance necessitate combination screening, with recent advancements enabling larger-scale studies.
Purpose of the Study:
- To review technological strategies for adapting PDOs to screening platforms.
- To discuss design considerations for combination screening using PDOs.
- To explore analytical methodologies, readout technologies, challenges, and future developments in PDO-based HTS.
Main Methods:
- Standardized matrices, smaller plate formats, and automation improve uniformity and workflow efficiency in PDO screening.
- Microfluidic systems offer precise concentration gradients and sequential treatment delivery for complex combination designs.
- Advanced assay readouts beyond viability, including label-free imaging and quantitative morphology, provide sensitive response measures.
Main Results:
- PDO-based HTS is a powerful approach for identifying and refining therapeutic combinations.
- Diverse analytics, including dose-response metrics and synergy calculations, are essential for understanding complex combination responses.
- Technological progress in standardization, automation, microfluidic delivery, and integrated analysis is key.
Conclusions:
- Ongoing advancements in PDO-based HTS platforms promise to accelerate the discovery of effective combination treatments.
- Improved assay standardization, automation, microfluidic delivery, and integrated analysis will enhance the translation of findings into precision medicine.
- PDO-based HTS facilitates the identification and optimization of combination therapies for improved patient outcomes.
